Therefore, targeting the regulation of AMPK and its synergistic signaling networks, such as peroxisome proliferator-activated receptor α (PPAR-α), while intervening in the oxidative stress-inflammation cascade, has become a new strategy for treating DCM. Here, PPARA is linked to familial dilated cardiomyopathy.